nach oben

Tipp

Herpes zoster rasch erkennen und effizient behandeln

Zeitschrift:: hautnah > Ausgabe 2/2019

Autor:: MD Prof. Dr. U. Wollina

Wichtige Hinweise

Erstveröffentlichung in MMW – Fortschritte der Medizin (2018). https://doi.org/10.1007/s15006-018-0006-2, geringfügig adaptiert.

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Jensen NJ, Rivailler P, Tseng HF, Quinlivan ML et al. Revisiting the genotyping scheme for varicella-zoster viruses based on whole-genome comparisons. J Gen Virol. 2017;98:1434–8 CrossRefPubMedPubMedCentral

Weinberg A, Canniff J, Rouphael N, Mehta A et al. Varicella-zoster virus-specific cellular immune responses to the live attenuated zoster vaccine in young and older adults. J Immunol. 2017;199:604–12 CrossRefPubMedPubMedCentral

Kurapati S, Sadaoka T, Rajbhandari L, Jagdish B et al. Role of the JNK pathway in varicella-zoster virus lytic infection and reactivation. J Virol. 2017;91:pii:e00640–17 CrossRefPubMedPubMedCentral

Silva JR, Lopes AH, Talbot J, Cecilio NT et al. Neuroimmune-glia interactions in the sensory ganglia account for the development of acute herpetic neuralgia. J Neurosci. 2017;37:6408–22 CrossRefPubMed

Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A et al. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis. 2017;17:356 CrossRefPubMedPubMedCentral

Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology. 2013;81:928–30 CrossRefPubMedPubMedCentral

Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170 CrossRefPubMedPubMedCentral

Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70:178–86 CrossRefPubMed

Hansson E, Forbes HJ, Langan SM, Smeeth L, Bhaskaran K. Herpes zoster risk after 21 specific cancers: population-based case-control study. Br J Cancer. 2017;116:1643–51 CrossRefPubMedPubMedCentral

10.

Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111:1806–15 CrossRefPubMed

11.

Winthrop KL, Yamanaka H, Valdez H, Mortensen E et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–84 CrossRefPubMedPubMedCentral

12.

Adelzadeh L, Jourabchi N, Wu JJ. The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. J Eur Acad Dermatol Venereol. 2014;28:846–52 CrossRefPubMed

13.

Schink T, Behr S, Thöne K, Bricout H, Garbe E. Risk of stroke after herpes zoster - evidence from a German self-controlled case-series study. PLoS One. 2016;11:e0166554 CrossRefPubMedPubMedCentral

14.

Marra F, Ruckenstein J, Richardson K. A meta-analysis of stroke risk following herpes zoster infection. BMC Infect Dis. 2017;17:198. CrossRefPubMedPubMedCentral

15.

Wollina U, Machetanz J. Herpes zoster and postzosterische Neuralgie. Hautarzt. 2016;67:653–65 CrossRefPubMed

16.

Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K et al. Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol. 2012;50:4120–2 CrossRefPubMedPubMedCentral

17.

Wollina U. Variations in herpes zoster manifestation. Indian J Med Res. 2017;145:294–8 PubMedPubMedCentral

18.

Arruti M, Piñeiro LD, Salicio Y, Cilla G et al. Incidence of varicella zoster virus infections of the central nervous system in the elderly: a large tertiary hospital-based series (2007–2014). J Neurovirol. 2017;23:451–9 CrossRefPubMed

19.

Werner RN, Nikkels AF, Marinovic B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol. 2017;31:9–19 CrossRefPubMed

20.

Ultsch B, Siedler A, Rieck T, Reinhold T et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173 CrossRefPubMedPubMedCentral

21.

Werner RN, Nikkels AF, Marinovic B, Schäfer M et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 2017;31:20–9 CrossRefPubMed

22.

Wollina U. Herpes zoster. In: Katsambas A, Lotti T, Dessinioti C, D’Erme AM (Eds). European Handbook of Dermatological Treatments. 3rd Edition. Springer: Berlin Heidelberg 2015: pp. 379–84 CrossRef

23.

Weaver BA, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (2011) Update on the advisory committee on immunization practices’ recommendations for use of herpes zoster vaccine. J Am Osteopath Assoc 2011;111(Suppl 6):S31–S33 PubMed

24.

Le P, Sabella C, Rothberg MB. Preventing herpes zoster through vaccination: New developments. Cleve Clin J Med. 2017;84:359–66 CrossRefPubMed

25.

Lal H, Cunningham AL, Godeaux O et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New Engl J Med. 2015;372:2087–96 CrossRefPubMed

26.

Cunningham AL, Lal H, Kovac M et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New Engl J Med. 2016;375:1019–32 CrossRefPubMed

27.

Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M. Herpes zoster vaccine: A health economic evaluation for Switzerland. Hum Vaccin Immunother. 2017;13:1495–1504 CrossRefPubMedPubMedCentral

28.

Hoshi SL, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35:3264–71 CrossRefPubMed

29.

Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G et al. Antiviral prophylaxis in patients with solid tumours and haematological malignancies–update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94:1441–50 CrossRefPubMedPubMedCentral

30.

Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75:207–15 CrossRefPubMed

31.

Lin HC, Chao YH, Wu KH, Yen TY et al. Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study. Medicine (Baltimore). 2016;95:e4037 CrossRef

32.

Tsai SY, Chen HJ, Lio CF, Ho HP et al. Increased risk of herpes zoster in patients with psoriasis: A population-based retrospective cohort study. PLoS One. 2017;12:e0179447 CrossRefPubMedPubMedCentral

33.

Ludvigsson JF, Choung RS, Marietta EV, Murray JA, Emilsson L. Increased risk of herpes zoster in patients with coeliac disease–nationwide cohort study. Scand J Public Health. 2017. https://doi.org/10.1177/1403494817714713 CrossRefPubMed

34.

Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open. 2017;7:e014032 CrossRefPubMedPubMedCentral

35.

Iglar K, Kopp A, Glazier RH. Herpes zoster as a marker of underlying malignancy. Open Med. 2013;7:e68–73 PubMedPubMedCentral

36.

Schmidt SA, Mor A, Schùnheyder HC, Sùrensen HT et al. Herpes zoster as a marker of occult cancer: A systematic review and meta-analysis. J Infect. 2017;74:215–35 CrossRefPubMed

37.

Lai SW, Lin CH, Lin HF, Lin CL et al. Herpes zoster correlates with increased risk of Parkinson’s disease in older people: A population-based cohort study in Taiwan. Medicine (Baltimore). 2017;96:e6075 CrossRef

38.

Lin TY, Yang FC, Lin CL, Kao CH et al. Herpes zoster infection increases the risk of peripheral arterial disease: A nationwide cohort study. Medicine (Baltimore). 2016;95:e4480 CrossRef

39.

England BR, Mikuls TR, Xie F, Yang S et al. Herpes zoster as a risk factor for incident giant cell arteritis. Arthritis Rheumatol. 2017. https://doi.org/10.1002/art.40236 CrossRefPubMedPubMedCentral

Titel: Herpes zoster rasch erkennen und effizient behandeln
Autor:: MD Prof. Dr. U. Wollina
Publikationsdatum: 19.11.2018
Schlagwörter: Herpesviren
Dermatologische Therapieverfahren
Infektionskrankheiten der Haut
DOI: https://doi.org/10.1007/s12326-018-0299-z
Verlag: Springer Vienna
Zeitschrift: hautnah Dermatologie, Allergologie und Ästhetische Medizin
Ausgabe 2/2019
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484

Bildnachweise

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Herpes zoster rasch erkennen und effizient behandeln

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Ohne Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Sind Neurodermitiker lebensmüder als hautgesunde Menschen?

Ulcus et dolor

Pektanginöse Beschwerden bei athletischem Patienten mit Psoriasis vulgaris

Welches Antibiotikum bei Erythema migrans?

Wundinfektion nach Hautkrebsoperationen in der täglichen Praxis eines Krankenhauses

Allergie auslösendes Protein der Knorpelfische weniger wirksam